Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer

By Boyraz Baris   Sendur Mehmet A.N.   Aksoy Sercan   Babacan Taner   Roach Emir C.   Kizilarslanoglu Muhammet C.   Petekkaya Ibrahim   Altundag Kadri  

Current Medical Research and Opinion, Vol. 29, Iss. 4, 2013-04 ,pp. : 405-414

Informa Healthcare

Access to resources Recommend Favorite

Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM)

By Willis Michael   Asseburg Christian   He Jianming  

Journal of Medical Economics, Vol. 16, Iss. 8, 2013-08 ,pp. : 1007-1021

Informa Healthcare

Access to resources Recommend Favorite

[HDL‐C/apoA‐I]: A multivessel cardiometabolic risk marker in women with T2DM

By  

DIABETES/METABOLISM: RESEARCH AND REVIEWS (ELECT), Vol. 34, Iss. 1, 2018-01 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effects of testosterone supplementation therapy on lipid metabolism in hypogonadal men with T2DM: a meta‐analysis of randomized controlled trials

By  

ANDROLOGY, Vol. 6, Iss. 1, 2018-01 ,pp. : 37-46

John Wiley & Sons Inc

Access to resources Recommend Favorite

T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial

By  

Reviews on Recent Clinical Trials, Vol. 12, Iss. 3, 2017-11 ,pp. : 216-222

Bentham Science Publishers

Access to resources Recommend Favorite